Dova Pharmaceuticals Inc (NASDAQ:DOVA) Major Shareholder Acquires $823,000.00 in Stock

Dova Pharmaceuticals Inc (NASDAQ:DOVA) major shareholder Life Sciences Maste Perceptive acquired 50,000 shares of the stock in a transaction on Friday, July 5th. The shares were bought at an average price of $16.46 per share, with a total value of $823,000.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Life Sciences Maste Perceptive also recently made the following trade(s):

  • On Wednesday, July 3rd, Life Sciences Maste Perceptive acquired 20,541 shares of Dova Pharmaceuticals stock. The shares were bought at an average price of $14.51 per share, with a total value of $298,049.91.
  • On Friday, June 28th, Life Sciences Maste Perceptive acquired 427,209 shares of Dova Pharmaceuticals stock. The shares were bought at an average price of $13.35 per share, with a total value of $5,703,240.15.

Dova Pharmaceuticals stock opened at $16.75 on Friday. The company has a market cap of $474.60 million, a price-to-earnings ratio of -6.44 and a beta of 2.55. The business has a fifty day simple moving average of $11.21. Dova Pharmaceuticals Inc has a 12 month low of $5.62 and a 12 month high of $26.49. The company has a current ratio of 4.46, a quick ratio of 4.27 and a debt-to-equity ratio of 0.20.

Dova Pharmaceuticals (NASDAQ:DOVA) last posted its earnings results on Tuesday, May 7th. The company reported ($0.58) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.10. The business had revenue of $4.00 million during the quarter, compared to analyst estimates of $3.46 million. Dova Pharmaceuticals had a negative return on equity of 87.20% and a negative net margin of 521.67%. On average, research analysts expect that Dova Pharmaceuticals Inc will post -2.1 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of DOVA. PNC Financial Services Group Inc. grew its stake in Dova Pharmaceuticals by 14,705.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 5,034 shares of the company’s stock worth $38,000 after purchasing an additional 5,000 shares in the last quarter. DekaBank Deutsche Girozentrale grew its stake in Dova Pharmaceuticals by 22.0% in the first quarter. DekaBank Deutsche Girozentrale now owns 13,300 shares of the company’s stock worth $336,000 after purchasing an additional 2,400 shares in the last quarter. Rhumbline Advisers grew its stake in Dova Pharmaceuticals by 46.1% in the fourth quarter. Rhumbline Advisers now owns 15,343 shares of the company’s stock worth $116,000 after purchasing an additional 4,843 shares in the last quarter. Two Sigma Investments LP bought a new position in Dova Pharmaceuticals in the fourth quarter worth approximately $136,000. Finally, Squarepoint Ops LLC bought a new position in Dova Pharmaceuticals in the fourth quarter worth approximately $137,000. 30.18% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have issued reports on the company. Evercore ISI upgraded Dova Pharmaceuticals from an “in-line” rating to an “outperform” rating and set a $15.00 price objective for the company in a research note on Monday, July 1st. BidaskClub upgraded Zillow Group from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 2nd. Wedbush set a $190.00 price objective on Home Depot and gave the company a “hold” rating in a research note on Wednesday, May 22nd. Zacks Investment Research cut ExlService from a “hold” rating to a “sell” rating in a research note on Wednesday. Finally, HC Wainwright lifted their price objective on Dova Pharmaceuticals from $18.00 to $39.00 and gave the company a “buy” rating in a research note on Thursday, June 27th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have issued a buy rating to the company. Dova Pharmaceuticals has a consensus rating of “Buy” and an average target price of $29.11.

About Dova Pharmaceuticals

Dova Pharmaceuticals, Inc, a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure.

Read More: What is the price-sales ratio?

Insider Buying and Selling by Quarter for Dova Pharmaceuticals (NASDAQ:DOVA)

Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.